Literature DB >> 24052775

Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety.

Steven Deitelzweig1.   

Abstract

BACKGROUND: Thromboprophylaxis with oral anticoagulants is an important but underused element of atrial fibrillation (AF) treatment. Reduction of stroke risk by anticoagulants comes at the price of bleeding risk. Patients with AF receiving anticoagulants require heightened attention with transition from one care setting to another.
METHODS: This review of the literature focuses on issues specific to the anticoagulation treatment of patients with AF.
RESULTS: Patients presenting for emergency care of anticoagulant-related bleeding should be triaged for the severity and source of the bleeding using appropriate measures, such as discontinuing the oral anticoagulant, administering vitamin K when appropriate to reverse warfarin-induced bleeding, or administering clotting factors for emergent bleeding. Reversal of oral anticoagulants in patients admitted to the hospital for surgery can be managed similarly to patients with bleeding, depending on the urgency of the surgical procedure. Patients with AF who are admitted for conditions unrelated to AF should be assessed for adequacy of stroke risk prophylaxis and bleeding risk. Newly diagnosed AF should be treated in nearly all patients with either warfarin or a newer anticoagulant.
CONCLUSIONS: Patient education is critically important with all anticoagulants. Close adherence to the prescribed regimen, regular international normalized ratio testing for warfarin, and understanding the stroke risk conferred by AF and aging are goals for all patients receiving oral anticoagulants. Detailed handoff from the hospitalist to the patient's primary care physician is required for good continuity of care. Monitoring by an anticoagulation clinic is the best arrangement for most patients. The elderly, particularly frail or debilitated patients who are transferring to long-term care, need a detailed transfer of information between settings, education for the patient and family, and medication reconciliation. Communication and coordination of care among outpatient, emergency, inpatient, subacute, and long-term care settings are vital in patients with AF who are receiving anticoagulants to balance stroke prevention and bleeding risk.

Entities:  

Keywords:  Anticoagulant drugs; atrial fibrillation; hemorrhage; stroke

Year:  2013        PMID: 24052775      PMCID: PMC3776521     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  73 in total

1.  A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin.

Authors:  H G Watson; T Baglin; S L Laidlaw; M Makris; F E Preston
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

2.  Improving care transitions: hospitalists partnering with primary care.

Authors:  Richard B Balaban; Mark V Williams
Journal:  J Hosp Med       Date:  2010-09       Impact factor: 2.960

Review 3.  Prohemostatic agents to prevent perioperative blood loss.

Authors:  Jerrold H Levy; Kenichi A Tanaka
Journal:  Semin Thromb Hemost       Date:  2008-10-27       Impact factor: 4.180

4.  Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall.

Authors:  Brian F Gage; Elena Birman-Deych; Roger Kerzner; Martha J Radford; David S Nilasena; Michael W Rich
Journal:  Am J Med       Date:  2005-06       Impact factor: 4.965

5.  Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.

Authors:  Karin S Coyne; Clark Paramore; Susan Grandy; Marco Mercader; Matthew Reynolds; Peter Zimetbaum
Journal:  Value Health       Date:  2006 Sep-Oct       Impact factor: 5.725

6.  The care transitions intervention: translating from efficacy to effectiveness.

Authors:  Rachel Voss; Rebekah Gardner; Rosa Baier; Kristen Butterfield; Susan Lehrman; Stefan Gravenstein
Journal:  Arch Intern Med       Date:  2011-07-25

7.  Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

Authors:  Wei Zhou; Sönke Schwarting; Sergio Illanes; Arthur Liesz; Moritz Middelhoff; Markus Zorn; Martin Bendszus; Sabine Heiland; Joanne van Ryn; Roland Veltkamp
Journal:  Stroke       Date:  2011-10-13       Impact factor: 7.914

8.  Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation.

Authors:  R J Patel; D M Witt; J J Saseen; D J Tillman; D S Wilkinson
Journal:  Pharmacotherapy       Date:  2000-10       Impact factor: 4.705

Review 9.  Status of the epidemiology of atrial fibrillation.

Authors:  William B Kannel; Emelia J Benjamin
Journal:  Med Clin North Am       Date:  2008-01       Impact factor: 5.456

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  6 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2013

2.  Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.

Authors:  Ragan Hart; David L Veenstra; Denise M Boudreau; Joshua A Roth
Journal:  Am J Med       Date:  2016-09-02       Impact factor: 4.965

3.  Improving Continuity of Care via the Discharge Summary.

Authors:  Farrant H Sakaguchi; Leslie A Lenert
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

Review 4.  Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.

Authors:  Walid Saliba
Journal:  Am J Cardiovasc Drugs       Date:  2015-10       Impact factor: 3.571

Review 5.  Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians.

Authors:  Joanne M Foody
Journal:  Clin Interv Aging       Date:  2017-01-23       Impact factor: 4.458

6.  Health literacy and knowledge in a cohort of Australian patients taking warfarin.

Authors:  Angela W Yiu; Beata V Bajorek
Journal:  Pharm Pract (Granada)       Date:  2018-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.